CADL - Candel Therapeutics Inc
IEX Last Trade
6.75
0.370 5.481%
Share volume: 342,735
Last Updated: Fri 30 Aug 2024 09:59:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.38
0.37
5.80%
Fundamental analysis
15%
Profitability
0%
Dept financing
12%
Liquidity
75%
Performance
15%
Performance
5 Days
18.84%
1 Month
14.02%
3 Months
-21.69%
6 Months
277.12%
1 Year
440.00%
2 Year
99.12%
Key data
Stock price
$6.75
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.66 - $14.30
52 WEEK CHANGE
$4.58
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: candeltx.com
Employees: 88
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: candeltx.com
Employees: 88
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Recent news